Recruiting artificial intelligence in battle against COVID-19 and future pandemics – Guardian
Developing an effective vaccine for the current pandemic as well as treatment options for COVID-19 patients is easier said than done. The drug discovery and development processes are by no means a walk through the park, even after a potential lead is identified, countless hurdles still need to be overcome before any drug makes it to the public.
Traditional new drug development is an expensive process and is comprised of a discovery phase that includes target-based drug screening and optimization, among other processes to identify candidates to advance towards further development. Subsequent drug development involves drug combination design with these candidates, and clinical trials. Unfortunately, success rates are very low, said Dean Ho of the National University of Singapore. Ho and his collaborator, Professor Xianting Ding of Shanghai Jiao Tong University, have turned to AI to solve this problem.
For rapidly spreading pathogens with unpredictable clinical courses, [such as the current SARS-CoV-2 outbreak], this process takes too long, even with the assistance of emerging technologies, added Ho.
Even re-purposing known drugs for combination therapies can be quite challenging as choosing the right combination as well as dosage precludes the optimization of treatment outcomes, said Ho. This also limits how many drugs can be simultaneously explored, as conventional drug screening protocols cannot cope with the large data pools that get generated as a result. Given this challenge, traditional new drug development and traditional repurposing are inherently sub-optimal, he added.
In a recent paper published in Advanced Therapeutics, the team developed an AI-based platform called Project IDentif. AI that was shown to quickly screen and identify viable combination therapies for the past, present, and future infections.
Using traditional re-purposing to address SARS or MERS would be very challenging due to the aforementioned issues, said Ding. However, with a platform like IDentif.AI, combination therapy optimisation could be accomplished within days. IDentif.AI is a disease-agnostic platform. As such, it does not have to be reprogrammed, and can be immediately deployed against any novel or established pathogen.
According to the team, the core importance of IDentif.AI is that it simultaneously reconciles the optimal drugs and doses against virtually any disease model from the aforementioned extraordinarily large drug/dose parameter spaces. When good drugs are given at the wrong dose, there may be no treatment efficacy at all, said Ho. At the same time, drug dosing may also have a role in determining which drugs belong in a combination in the first place. Therefore, simultaneously pinpointing the right drugs and doses is absolutely essential.
To run a search, a small set of pre-designed combinations of drugs is given to provide a sample of the drug-dose parameter space. Imagine filling up an entire room with tiny marbles, with each marble representing a possible drug-dose combination. Our job is to find ranked list of best to worst marbles from a room filled with billions of them. This pre-designed set of combinations doesnt pinpoint every single one of them, but at least samples enough of the space to guide us to where the best one is and tells us the drugs/dosages of that optimal combination, explained Ding.
After this first set of experiments is done and the full drug-dose space is essentially mapped out for us, IDentif.AI operates off the concept that drugs and doses (inputs) are related to treatment outcomes (e.g., antiviral activity, drug toxicity) using a smooth quadratic surface (resembling a smooth mountain with one peak), added Ho. This surface is calibrated and mapped out by these set of unique initial experiments such as preventing a virus from infecting a healthy cell or shrinking a tumour (maximizing efficacy), or preventing healthy cell death (minimizing toxicity), etc.).
The map is therefore unique to every study, using different drugs and disease models, and can represent a population of cells, animals, people, or even a single patient, says Ding. To develop a population-optimized regimen, we can take biological samples pooled from a population of patients. This pooled sample can be run against a standardized cell infection model and within days, a combination will be derived. The surface map will be based on the viral/infected cell population represented by a large population of patients.
For a personalized case, if there is a patient with a high viral load, we can run the test using only their own sample, and within days, we can develop a regimen just for that patient, and the surface map will be represented by only their own sample.
And not every single drug combination needs to be screened, as once the team runs a threshold number of experiments, the map can be created and used to guide the team through the rankings of best to worst combinations based on optimal inhibition of infection and minimal toxicity.
What is really neat about IDentif.AI its ability to interrogate such as huge drug-dose space, which has already directly led to successful clinical outcomes and other indications, said Ho. As proof of concept, the team was able to identify an effective combination therapy that successfully inhibited A549 lung cell infection by the vesicular stomatitis virus (VSV) within three days of project. This compared to the months or even years that conventional drug discovery searches require, which are still only capable of exploring a tiny chemical space with poor clinical outcomes, demonstrates this technologys critical importance.
The reality is that the world will be confronted with challenges such as COVID-19 again, said Ho. We simply dont have the time or resources to wait for vaccines or antibody therapy every time. Lessons learned from COVID-19 have shown us that we cannot continue to relinquish valuable time in identifying optimal repurposed combinations. This will not solve the problem and will lead to drug shortages when some could have in fact been used correctly if a systematic optimization process was conducted.
IDentif.AI is also being adapted for additional pathogens such as Dengue fever and even the possibility of a SARS-CoV-2 mutation. If it mutates to a stage where a novel combination will be needed, IDentif.AI will be prepared to rapidly respond, said Ho.
Our aim is to give Project IDentif.AI to the world so that the next epidemic can potentially be contained or prevented using rapidly optimized drug repurposing. Implementing IDentif.AI is remarkable, rapid, and economical. As such, our work has involved healthcare economics, global health security, and surveillance experts to help us develop strategies to scale this towards widespread use on a cost-neutral basis.
More:
Recruiting artificial intelligence in battle against COVID-19 and future pandemics - Guardian
- Senate bill targets the use of artificial intelligence in Mississippi - WAPT Jackson - March 15th, 2025 [March 15th, 2025]
- will.i.am and Sean Paul on embracing artificial intelligence in music - Sky News - March 15th, 2025 [March 15th, 2025]
- As Artificial Intelligence (AI) Stocks Fall, Investors Should Consider Buying More of These 2 Powerhouses - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- FSUs Graduate School hosts workshop on artificial intelligence to explore the impact of AI on teaching and research - Florida State News - March 15th, 2025 [March 15th, 2025]
- Artificial Intelligence Optimization (AIO): The Next Frontier in SEO - hackernoon.com - March 15th, 2025 [March 15th, 2025]
- The U.S. Army, Artificial Intelligence, and Mission Command - War On The Rocks - March 15th, 2025 [March 15th, 2025]
- 2 Stock-Split Artificial Intelligence (AI) Stocks to Buy Before They Zoom Higher, According to Wall Street Analysts - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- AI in the classroom: How artificial intelligence is helping teachers - Bay News 9 - March 15th, 2025 [March 15th, 2025]
- Video: Daryl Morey Says 76ers Use Artificial Intelligence for Input on Team Decisions - Bleacher Report - March 15th, 2025 [March 15th, 2025]
- Better Artificial Intelligence Stock: AT&T vs. Verizon Communications - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- NVIDIA GTC 25: What To Expect From the Years Biggest Artificial Intelligence Event - BizTech Magazine - March 15th, 2025 [March 15th, 2025]
- 2 Stock-Split Artificial Intelligence (AI) Stocks to Buy Before They Zoom Higher, According to Wall Street Analysts - MSN - March 15th, 2025 [March 15th, 2025]
- DEI Erosion Threatens Safety. Artificial Intelligence May Help Pick Up the Slack. - Inbound Logistics - March 15th, 2025 [March 15th, 2025]
- Saint Vincent conference will examine broad impact of artificial intelligence - TribLIVE - March 15th, 2025 [March 15th, 2025]
- As Artificial Intelligence (AI) Stocks Fall, Investors Should Consider Buying More of These 2 Powerhouses - MSN - March 15th, 2025 [March 15th, 2025]
- 3 Artificial Intelligence (AI) Stocks You Can Buy and Hold for the Next Decade - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- This Artificial Intelligence (AI) Stock Has Surged 1,000% Over the Past 2 Years. Is a Split on the Horizon? - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- Move Over, Artificial Intelligence (AI) -- Businesses Are on Pace to Spend More Than $10 Trillion on This Trend Over the Next Decade - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- Here Is My Top Artificial Intelligence (AI) Stock to Buy Right Now - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- Nasdaq Sell-Off: 2 Artificial Intelligence (AI) Stocks Down 20% and 49% to Buy Hand Over Fist on the Dip - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- 1 Top Artificial Intelligence (AI) Chip Stock to Buy Hand Over Fist Before It Jumps - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- [Latest] How Artificial Intelligence is Shaping the Emc Shielding And Test Equipment Market - openPR - March 15th, 2025 [March 15th, 2025]
- Nasdaq Correction: 5 Reasons Nvidia Stock Is Still a Top Artificial Intelligence (AI) Stock to Buy Right Now - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- Artificial Intelligence (AI) Adoption Rates Appear Low, but This Technology Leader Could See a Massive Surge in Demand in the Next 10 Years. Here's... - March 15th, 2025 [March 15th, 2025]
- [Latest] The Influence of Artificial Intelligence on the Augmented Reality (Ar) Shopping Market - openPR - March 15th, 2025 [March 15th, 2025]
- Oracle Just Shared Some Amazing News for the Entire Artificial Intelligence (AI) Industry - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- 1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- Inside The Artificial Intelligence That Can Clone Your Mind - Forbes - March 15th, 2025 [March 15th, 2025]
- Why Tesla Could Be a Massive Winner in the Artificial Intelligence (AI) Race - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- 4 Artificial Intelligence (AI) Stocks Worth Buying in the Tech Sell-Off - The Motley Fool - March 15th, 2025 [March 15th, 2025]
- Impact of Artificial Intelligence (AI) on Media and Creative Industries - EDMO - March 1st, 2025 [March 1st, 2025]
- 1 Artificial Intelligence (AI) Stock That Could Be Bigger Than Nvidia in 5 Years - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- This Artificial Intelligence (AI) Stock Is Up 15% in 2025 Already. It Is Still a Solid Buy? - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- Can artificial intelligence be the future solution to the enormous challenges and suffering caused by Schizophrenia? - Nature.com - March 1st, 2025 [March 1st, 2025]
- Applications of Artificial Intelligence in Medical Education: A Systematic Review - Cureus - March 1st, 2025 [March 1st, 2025]
- This Artificial Intelligence (AI) Stock Is Up 15% in 2025 Already. It Is Still a Solid Buy? - AOL - March 1st, 2025 [March 1st, 2025]
- Federal Executive Forum Artificial Intelligence Strategies in Government Progress and Best Practices 2025 - Federal News Network - March 1st, 2025 [March 1st, 2025]
- Introduction to Artificial Intelligence for General Surgeons: A Narrative Review - Cureus - March 1st, 2025 [March 1st, 2025]
- How is Artificial Intelligence Affecting Health Care? - Workers Comp Forum - March 1st, 2025 [March 1st, 2025]
- 1 Spectacular Artificial Intelligence (AI) Stock to Buy With $50 Right Now - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- 20+ Advantages and Disadvantages of AI | Pros of Artificial Intelligence - Simplilearn - March 1st, 2025 [March 1st, 2025]
- Prediction: This Top Artificial Intelligence (AI) Stock Will Start Skyrocketing After March 6 - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- 1 Surprising Stock Harnessing the Power of Artificial Intelligence (AI) - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- 2 Top Artificial Intelligence (AI) Stocks to Buy On the Dip Amid Nasdaq Selloff - Yahoo Finance - March 1st, 2025 [March 1st, 2025]
- Review: Artificial intelligence is shaping the future of diabetes care - News-Medical.Net - March 1st, 2025 [March 1st, 2025]
- Prediction: This Artificial Intelligence (AI) Stock -- a 1,020% Gainer Since Its IPO -- Won't Split Its Stock in 2025. Here's Why - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- A Nobel laureate on the economics of artificial intelligence - MIT Technology Review - March 1st, 2025 [March 1st, 2025]
- Prediction: This Top Artificial Intelligence (AI) Stock Will Start Skyrocketing After March 6 - Nasdaq - March 1st, 2025 [March 1st, 2025]
- Meta Platforms Just Caused This Crucial Artificial Intelligence (AI) Stock to Plummet. Should You Buy the Dip? - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- Artificial Intelligence - AI Update, February 28, 2025: AI News and Views From the Past Week - MarketingProfs.com - March 1st, 2025 [March 1st, 2025]
- The Ultimate Artificial Intelligence (AI) ETF to Buy With $50 Right Now - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- Prediction: This Artificial Intelligence (AI) Company Will Split Its Stock in 2025 - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- Should You Forget Nvidia and Buy 2 Artificial Intelligence (AI) Stocks Instead? - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- Why Artificial Intelligence Stocks SoundHound AI, IonQ, and C3.ai Are Struggling Today - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- 2 Top Artificial Intelligence (AI) Stocks Ready for a Bull Run - The Motley Fool - March 1st, 2025 [March 1st, 2025]
- AI Cant Do This Anymore: The Dangers of Artificial Intelligence in Academia - Skidmore News - March 1st, 2025 [March 1st, 2025]
- Whats Next in Artificial Intelligence: Agents that can do more than chatbots - Pittsburgh Post-Gazette - February 9th, 2025 [February 9th, 2025]
- Geopolitics of artificial intelligence to be focus of major summit in Paris; AP explains - Yahoo - February 9th, 2025 [February 9th, 2025]
- Geopolitics of artificial intelligence to be focus of major summit in Paris; AP explains - The Associated Press - February 9th, 2025 [February 9th, 2025]
- 3 Top Artificial Intelligence Stocks to Buy in February - MSN - February 9th, 2025 [February 9th, 2025]
- Geopolitics of artificial intelligence to be focus of major summit in Paris; AP explains - Lufkin Daily News - February 9th, 2025 [February 9th, 2025]
- 2 of the Hottest Artificial Intelligence (AI) Stocks on the Planet Can Plunge Up to 94%, According to Select Wall Street Analysts - The Motley Fool - February 9th, 2025 [February 9th, 2025]
- These 2 Stocks Are Leading the Data Center Artificial Intelligence (AI) Trend, but Are They Buys Right Now? - The Motley Fool - February 9th, 2025 [February 9th, 2025]
- Book Review | Genesis: Artificial Intelligence, Hope, and the Human Spirit - LSE - February 9th, 2025 [February 9th, 2025]
- The Artificial Intelligence Action Summit In France: Maintaining The Dialogue On Global AI Regulation - Forrester - February 9th, 2025 [February 9th, 2025]
- Is prediction the next frontier for artificial intelligence? - Healthcare IT News - February 9th, 2025 [February 9th, 2025]
- The Artificial Intelligence in Medicines Market Is Set to Reach $18,119 Million | CAGR of 49.6% - openPR - February 9th, 2025 [February 9th, 2025]
- Geopolitics of artificial intelligence to be focus of major summit in Paris; AP explains - The Audubon County Advocate Journal - February 9th, 2025 [February 9th, 2025]
- Around and About with Richard McCarthy: Asking AI about itself: Will artificial intelligence ever surpass humankind? - GazetteNET - February 9th, 2025 [February 9th, 2025]
- Will the Paris artificial intelligence summit set a unified approach to AI governanceor just be another conference? - Bulletin of the Atomic... - February 9th, 2025 [February 9th, 2025]
- Apple Stock Jumps on Artificial Intelligence (AI) Driving iPhone Sales. Here's Why It's Not Getting Crushed by the DeepSeek Launch. - The Motley Fool - February 9th, 2025 [February 9th, 2025]
- Who will win the race to Artificial General Intelligence? - The Indian Express - February 9th, 2025 [February 9th, 2025]
- Prediction: This Artificial Intelligence (AI) Chip Stock Will Win Big From DeepSeek's Feat - The Motley Fool - February 9th, 2025 [February 9th, 2025]
- Prediction: 2 Artificial Intelligence (AI) Stocks That Will Be Worth More Than Nvidia 3 Years From Now - The Motley Fool - February 9th, 2025 [February 9th, 2025]
- State of Louisiana Launches Innovation Brand, Announces Creation of $50 Million Growth Fund and Artificial Intelligence Research Institute - Louisiana... - February 9th, 2025 [February 9th, 2025]
- Using smart technologies and artificial intelligence in food packaging can reduce food waste - Yahoo News Canada - February 9th, 2025 [February 9th, 2025]
- BigBear.ai Wins Department of Defense Contract to Prototype Near-Peer Adversary Geopolitical Risk Analysis for Chief Digital and Artificial... - February 9th, 2025 [February 9th, 2025]
- Should Investors Change Their Artificial Intelligence (AI) Investment Strategy After the DeepSeek Launch? - The Motley Fool - February 9th, 2025 [February 9th, 2025]
- 1 Unstoppable Artificial Intelligence (AI) Stock to Buy Before It Punches Its Ticket to the $4 Trillion Club - The Motley Fool - February 9th, 2025 [February 9th, 2025]
- Got 10 Years and $1000? These 3 Artificial Intelligence (AI) Stocks Are Set to Soar. - The Motley Fool - February 9th, 2025 [February 9th, 2025]